Advanced Search
Users Online: 300
Home
About us
Editorial board
Ahead of print
Current issue
Search
Archives
Submit article
Instructions
Subscribe
Contacts
Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Most cited articles *
Archives
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Cited
Viewed
PDF
ORIGINAL ARTICLES
Tuberculin purified protein derivative immunotherapy in the treatment of viral warts
Ajay Nimbalkar, Sushil Pande, Ramesh Sharma, Milind Borkar
January-June 2016, 2(1):19-23
DOI
:10.4103/2455-3972.184103
Introduction:
Viral warts are caused by human papillomavirus. Although various treatment modalities are available, many of them result in the partial clearance of warts or recurrence. Immunotherapy has been tried in the recent times with variable success rates. We undertook a study to evaluate the safety and efficacy of immunotherapy using tuberculin purified protein derivative (PPD) for the treatment of viral warts.
Materials and Methods:
A total of 45 patients were included in the study. Each patient was injected with 10 TU of tuberculin PPD (0.1 ml) intralesionally in the largest wart at 2 weekly interval. A total of maximum six treatment sessions were conducted. Resolution of viral warts was considered as the clinical end point of the study. The clinical assessment was done by photographic measurements at baseline, before each treatment session, and 3 weeks after the completion of treatment.
Results:
A total of 62.2% patients (28 out of 45) showed complete clearance at injected and distant warts, eight patients (17.8%) showed partial clearance, and nine patients (20%) showed no improvement. No significant side effects were observed except for localized hair loss around injected viral wart over the scalp.
Conclusion:
Tuberculin PPD immunotherapy was found to be a safe and effective treatment modality for the treatment of viral warts.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
6
10,608
518
REVIEW ARTICLES
Itraconazole: What clinicians should know?
Piet De Doncker, Sushil Pande, Ute Richarz, Nishant Garodia
January-June 2017, 3(1):4-10
DOI
:10.4103/ijdd.ijdd_20_17
Our purpose in assembling this paper is 2-fold. First, we hope to review in-depth the properties on itraconazole pellet-capsules and what clinicians should know when considering oral itraconazole and discuss the potential value of treating superficial dermatophyte infections with oral antifungal therapy. Second, we hope to address some of the concerns of the recent epidemic of chronic recalcitrant widespread dermatophytosis in India, with emphasis on better treatment but also considering some of the necessary prophylaxis hygiene measures. An in-depth review of itraconazole (as pellet-capsules), a triazole antifungal will be presented with focus on the pharmacokinetic properties which lead to the development of the 1-week pulse dosing for skin and nail infections. Finally, recommendations for best usage of itraconazole pellet-capsules for management of dermatophytosis will be summarized in this paper.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
6
12,710
1,404
REVIEW ARTICLE
Apremilast: A dermatologic perspective
Aditya Kumar Bubna
July-December 2016, 2(2):75-82
DOI
:10.4103/2455-3972.196166
Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administration in the management of psoriatic arthropathy (PsA). As biologic therapy is associated with significant amounts of adverse effects, newer treatment options with an efficacious outcome, sans the toxicity, is something all clinicians would implement readily in their therapeutic regimens. Apremilast is one such drug which has shown promise in the management of psoriasis, PsA, and a few other dermatologic disorders. This review will throw light on the dermatologic perspective regarding apremilast.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
5
13,906
1,592
EDITORIAL
Steroid containing fixed drug combinations banned by government of India: A big step towards dermatologic drug safety
Sushil Pande
January-June 2016, 2(1):1-2
DOI
:10.4103/2455-3972.184102
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
4
7,883
322
Clinical failure of antifungal therapy of dermatophytoses: Recurrence, resistance, and remedy
Ragunatha Shivanna, Arun C Inamadar
January-June 2017, 3(1):1-3
DOI
:10.4103/ijdd.ijdd_13_17
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
3
8,311
944
Tranexamic acid in melasma: Why and how?
Shuken Dashore, Katyain Mishra
July-December 2017, 3(2):61-63
DOI
:10.4103/ijdd.ijdd_37_17
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
3
49,903
1,132
ORIGINAL ARTICLES
A clinical study of severe cutaneous adverse drug reactions and role of corticosteroids in their management
Rohini Sharma, Naina Dogra, Devraj Dogra
January-June 2017, 3(1):20-23
DOI
:10.4103/ijdd.ijdd_22_16
Background:
Various medications are used for the treatment of various diseases. Ironically, adverse drug reactions (ADRs) also accompany the use of these medications and are as old as the medicine itself. These drug reactions can range from mild transient erythema at one end of the spectrum to severe cutaneous ADRs (SCADRS) that include Steven–Johnson syndrome (SJS), toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms complex (DRESS).
Aim:
This study aims to study the clinical and epidemiological aspects of severe cutaneous adverse drug reactions (SCADRS) at a referral center of Jammu region, with special reference to the role of corticosteroids in the management.
Materials and Methods:
The study was carried out between July 2015 and December 2015, at a tertiary hospital after permission from Ethical Committee of the institution. A total of 44 patients were included in the study which included outpatients as well as inpatients admitted after written informed consent. The Naranjo ADR probability scale was applied to indicate the causality of the drug with the SCADRS.
Results:
In the study, a total of 44 patients were included in the study. Males outnumbered the females, and maximum patients were in the age group of 21–40 years. SJS was the most common SCARD found followed by DRESS. Antiepileptic class of drug was found to be most commonly implicated. Immediate withdrawal of the culprit drug and administration of systemic steroids reverted the SCARD in maximum patients.
Conclusion:
Severe cutaneous adverse drug reactions can be associated with serious morbidity as well as mortality. Their knowledge and prompt recognition are essential for clinicians as early recognition, and immediate withdrawal of the culprit drug/drugs with adequate management can be lifesaving.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
3
2,030
197
BRIEF REPORT
Successful use of oral acitretin in oral lichen planus
Ajay Deshpande
January-June 2017, 3(1):24-27
DOI
:10.4103/ijdd.ijdd_9_17
Lichen planus is a common inflammatory disorder affecting skin, mucus membranes, nails, and hair. At least two-thirds of cases occur between 30 and 60 years of age. Lichen planus can affect the mucosal surfaces of mouth, genitalia, conjunctiva, esophagus, anus, and urethra. Oral lichen planus is relatively common than lichen planus of other mucosal areas. Oral lichen planus is very refractory to treatment. Oral and topical steroids, topical tacrolimus, azathioprine, cyclosporine, and dapsone are the drugs used to treat oral lichen along with acitretin. We hereby report the successful treatment of oral lichen planus with acitretin in three patients.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
2
4,768
185
ORIGINAL ARTICLES
Effect of measles mumps rubella vaccine in treatment of common warts
Anuja Dhope, Bhushan Madke, Adarsh Lata Singh
January-June 2017, 3(1):14-19
DOI
:10.4103/ijdd.ijdd_1_17
Background:
There are many destructive and immunotherapeutic options available for the treatment of common warts, but no treatment is 100% effective and usually cause pain and scarring. Recently, intralesional immunotherapy with skin test antigens and vaccines has been shown to be effective in the management of warts. We evaluated the efficacy of Measles Mumps Rubella (MMR) vaccine injection in the treatment of cutaneous warts.
Aim:
To study the efficacy of intralesional MMR vaccine in the treatment of common warts.
Materials and Methods:
A case–control study was conducted in AVBR Hospital, Sawangi (Meghe), Wardha, in 2015–2016. Forty clinically diagnosed cases of cutaneous common wart were selected in the study and were put randomly into two groups (20 in each group). Group 1: included twenty patients subjected to intralesional injection of 0.5 ml MMR vaccine. Group 2: included twenty patients as a control group and subjected to intralesional injection of 0.5 ml saline. These injections were repeated every 3 weeks intervals for maximum three injections. Follow-up of patients was done every 6 months for clinical assessment of results and to study recurrence.
Results:
A significant difference was found between the therapeutic responses of common warts to MMR. Vaccine and normal saline (control) group. At the end of 9 weeks (third visit), about 65% patients treated with MMR vaccine showed complete clearance compared with 5% of the control group. Grade 3 response was 20% versus 10% respectively; whereas Grade 2 response was observed in 10% versus 25%, respectively, and as regards no response, it was 5% versus 60% in MMR vaccine and control group, respectively.
Conclusion:
We found that the treatment of common warts by MMR vaccine is effective, with good cure rates, and excellent safety profile.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
2
11,070
462
A study of clinical patterns and causative agents of adverse cutaneous drug reactions
Nilesh Mahatme, R Narasimharao
January-June 2016, 2(1):13-18
DOI
:10.4103/2455-3972.184088
Background:
Cutaneous eruptions are the most frequently reported adverse reactions to drugs. The pattern of cutaneous adverse drug reactions (CADRs) and the causative drugs keeps changing every year.
Objective:
The study was designed to ascertain the different clinical patterns of CADRs and to determine the causative agents.
Materials and Methods:
A prospective observational nonrandomized hospital-based study was carried out over a period of 6 months. The CADRs as observed in the outpatient and inpatient Departments of Dermatology were recorded. Naranjo's algorithm was used to determine the causality assessment. Clinical pattern of these adverse drug cutaneous reactions was studied. Causality assessment was done with the help of Naranjo's algorithm.
Results:
A total of fifty patients diagnosed to have CADRs were included in the study. The most common type of CADRs was urticaria (30%) followed by fixed drug eruption (FDE) (24%) and maculopapular eruption (12%). Antimicrobial agents (AMAs) (48%) were responsible for majority of the detected reactions, followed by nonsteroidal anti-inflammatory drugs (24%), antihypertensives (8%), and antiepileptics (4%). A total of 41 reactions (82%) showed probable causal association, 4 reactions had possible association (8%), and 5 cases of cutaneous drug reaction (10%) showed definite causal association with the drug.
Conclusion:
A wide clinical spectrum of CADRs ranging from FDE to mild maculopapular rash to serious Stevens–Johnson syndrome was observed. Most of these drug eruptions were caused by AMAs. The occurrence of CADRs in the present study was in concurrence to various studies conducted in India.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
2
2,414
250
REVIEW ARTICLE
Bilastine: A novel antihistamine
Jeet Gandhi, Kiran Godse, Gauri Godse
January-June 2018, 4(1):3-6
DOI
:10.4103/ijdd.ijdd_12_18
Bilastine is a new second generation H1-antihistamine approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU) in patients older than 12 years of age. AR and urticaria are very common clinical conditions that represent one of the most frequent reasons for a patient to visit their general practitioner or allergist or dermatologist. Bilastine, with its efficacy and safety profile epitomizes the evolution of research on antihistamines.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
2
18,887
1,257
VIVA VOCE
Rituximab in the treatment of skin diseases
Murlidhar Rajagopalan, Resham Vasani
July-December 2017, 3(2):105-109
DOI
:10.4103/ijdd.ijdd_31_17
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
2
4,808
467
CASE REPORTS
Generalized bullous fixed drug reaction: A close similarity to stevens–johnson syndrome
Bhagyashri Daulatabadkar, Sushil Pande, Milind Borkar
January-June 2017, 3(1):28-31
DOI
:10.4103/ijdd.ijdd_11_17
Generalized bullous fixed drug eruption is bullous type of fixed drug eruption characterized by sharply defined bullae at the same site following administration of offending drug. GBFDE has aggressive course unlike conventional FDE and requires aggressive treatment. Mucosa is usually spared and constitutional symptoms are mild. We came across two cases of GBFDE in which culprit drugs were B-Lactam antibiotics.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
6,590
276
Nicolau syndrome: A rarely seen iatrogenic fatal cutaneous reaction following intramuscular diclofenac injection
Anup Kumar Tiwary, Rohit K Aggarwal
July-December 2016, 2(2):99-101
DOI
:10.4103/2455-3972.196171
Nicolau syndrome, also known as embolia cutis medicamentosa or livedoid dermatitis, is a rare cutaneous adverse drug reaction seen at the site of injection of some particular drugs. It was first reported by Freudenthal in 1924 and Nicolau in 1925 as an adverse effect of bismuth salts used in syphilis. Typically, this syndrome is clinically manifested by intense burning or stabbing pain at the site of injection and retiform hemorrhagic patches with or without vesiculations and ulceration with a variable degree of tissue necrosis. To the best of our knowledge, <50 cases of Nicolau syndrome have been reported in medical literature which occurred following intramuscular administration of diclofenac sodium. Here, we report a 26-year-old female typically presenting with pathognomic signs and symptoms of NS after taking intramuscular injection of diclofenac.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
2,013
114
EDITORIAL
Purified protein derivative immunotherapy for viral warts and interpretation of tuberculin skin tests and interferon gamma release assay for diagnosis of tuberculosis in India
Sushil Pande, Anil Sontakke, BO Tayade
July-December 2016, 2(2):73-74
DOI
:10.4103/2455-3972.196165
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
1,982
139
Omalizumab in the treatment of chronic urticaria
Kiran Godse
January-June 2018, 4(1):1-2
DOI
:10.4103/ijdd.ijdd_19_18
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
4,684
301
Topical sirolimus in the treatment of facial angiofibromas
Resham Vasani
July-December 2018, 4(2):49-51
DOI
:10.4103/ijdd.ijdd_34_18
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
2,903
198
LETTERS TO EDITOR
Good response to oral acitretin monotherapy in a case of verrucous carcinoma of sole
Rameshwar Gutte, Bhushan Madke
January-June 2018, 4(1):29-30
DOI
:10.4103/ijdd.ijdd_14_17
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
569
51
Symmetrical drug related intertriginous and flexural exanthema after ranitidine therapy: A probable causal association in an 18-year-old girl
Nidhi Yadav, Sumit Kar, Varsha Verma, Komal Ramteke
January-June 2018, 4(1):34-36
DOI
:10.4103/ijdd.ijdd_33_17
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
1,061
64
Azathioprine-induced alopecia as an early clinical marker of its myelotoxicity
Anil B Bhokare
January-June 2017, 3(1):40-41
DOI
:10.4103/ijdd.ijdd_4_17
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
13,379
120
Urticarial rash after tranexamic acid infusion
Raghavendra Vagyannavar, Rekha Devi, Vandna Bharti
January-June 2017, 3(1):43-44
DOI
:10.4103/ijdd.ijdd_5_17
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
1,139
56
Levetiracetam-induced maculopapular rash: A rare side effect
Mahesh M Unni, Dinesh Verma, Ruikar Devashish
July-December 2016, 2(2):109-111
DOI
:10.4103/2455-3972.196204
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
3,977
97
MANAGING A SIDE EFFECT
Oral retinoid-induced cheilitis
Bhushan Madke, Hiral Shah, Adarsh Lata Singh, Meenaz Khoja, Poonam Kabra
January-June 2016, 2(1):50-53
DOI
:10.4103/2455-3972.184104
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
5,462
226
ORIGINAL ARTICLES
Clinical spectrum of cutaneous adverse drug reactions
Ankita Agrawal, Smita Ghate, Abhishek Kumar Gupta, Rachita Dhurat
July-December 2018, 4(2):61-66
DOI
:10.4103/ijdd.ijdd_14_18
Background:
Cutaneous adverse drug reactions (CADRs) are common, comprising 10%–30% of all reported adverse drug reactions (ADRs) and its incidence in hospitalized patients is 2%–3%.
Aims:
The aim is to study the different clinical spectrum of CADRs in outpatient and inpatient and to find out the offending drug.
Settings and Design:
A prospective observational, nonrandomized hospital-based study was conducted at a tertiary care hospital over a period of 12 months.
Materials and Methods:
Patients presenting with suspected drug-related cutaneous lesions were included if drug identity could be ascertained. Clinical profiling was done. The severity of the reaction was assessed using modified Hartwig and Siegel ADR severity assessment scale.
Statistical Analysis Used:
Data were analyzed using Stata Version 13.
Results:
Out of the total study population, most commonly observed cutaneous ADRs were fixed drug reaction in 28.75%, followed by maculopapular drug rash in 26.3%, and urticarial rash in 20.6%. Few less frequently observed CADRs were a lichenoid eruption, acneiform eruption, and baboon syndrome, generalized pruritus, pityriasis rosea, and vasculitis. Antimicrobials accounted for 37.5% of the total followed by nonsteroidal anti-inflammatory drugs 25%, anti-epileptics 12.5%, and antifungal 6.25%. Anti-retroviral therapy contributed 3.125%, whereas 1.875% were due to Anti-Koch's therapy. About 28.1% of patients were taking monotherapy, whereas 71.9% of patients were received polytherapy.
Conclusions:
Wide spectrums of drug reaction were observed in this study. Sound knowledge of these drug eruptions may help the clinician to diagnose and effectively manage their cases. Polypharmacy is a well-known predictor of ADRs in children and adults.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
2,370
256
VIVA VOCE
Viva Voce on omalizumab
Kiran Godse, Resham Vasani
July-December 2016, 2(2):121-123
DOI
:10.4103/2455-3972.196227
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
2,280
236
* Source: CrossRef
Sitemap
|
What's New
|
Feedback
|
Disclaimer
© Indian Journal of Drugs in Dermatology | Published by Wolters Kluwer -
Medknow
Online since 26
th
November, 2015